Yumanity set to earn $500 million from deal with Merck

24 June 2020

US neuroscience-focused start-up Yumanity Therapeutics has entered into a strategic research collaboration and license agreement with pharma giant Merck & Co (NYSE: MRK) focused on accelerating the development of new treatments for neurodegenerative diseases.

Under the terms of the accord, Merck will gain exclusive rights to two novel Yumanity pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD). Yumanity and Merck will collaborate to advance the two pre-clinical programs during the research term, after which Merck has the right to continue clinical development and commercialization.

Under the collaboration agreement, Yumanity will receive an upfront payment and is eligible to receive milestone payments totaling around $500 million associated with the successful development of marketed products for pipeline programs, as well as royalties on net sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK